π’ Part of our 100% Free MCCQE1 Question Bank. No registration required.
Internal Medicine is the largest and most heavily tested specialty in the MCCQE1 exam. Mastering these high-yield topics is essential for IMGs preparing for Canadian medical licensure.
π Key Topics for MCCQE1
Chest pain approach: ACS, STEMI vs NSTEMI, unstable angina management
STEMI: Door-to-balloon time <90 min, aspirin + P2Y12 inhibitor immediately
Heart Failure exacerbation: IV furosemide first, check BNP, avoid NSAIDs
DKA: Anion gap acidosis, glucose >11, ketones β give IV fluids first, then insulin
Hypothyroidism: Levothyroxine on empty stomach, check TSH after 6 weeks
PE massive: Hypotension + tachycardia + hypoxia β thrombolytics if no CI
AKI prerenal: BUN:Cr ratio >20, FeNa <1%, responds to IV fluids
π Quick Reference Table
Condition
First-line Treatment
Key Drug/Action
Hypertension + DM
ACE inhibitor or ARB
Renal protection
Heart Failure rEF
ACEi + BB + diuretic
Reduce mortality
Type 2 DM
Metformin
First-line always
CAP mild
Amoxicillin
Outpatient
CAP moderate
Azithromycin + beta-lactam
Inpatient
DVT/PE
LMWH then DOAC
Anticoagulation
Hyperkalemia (Severe)
Calcium Gluconate
Cardiac membrane stabilization
Thyroid Storm
Beta-blocker + PTU + Iodine
Multi-step management
π Sample High-Yield Question
Q: A 65-year-old male with a history of heart failure presents with worsening shortness of breath. On exam, he has bilateral crackles and 2+ pitting edema. JVP is elevated. Which of the following is the most appropriate next step in management?
A) Start Oral Spironolactone
B) IV Furosemide
C) Increase Bisoprolol dose
D) Order a Chest CT
Explanation: In acute decompensated heart failure (ADHF), the priority is volume management. IV diuretics are the first-line therapy to reduce congestion.
π Advanced Therapeutic Trends:
Stay updated on Biological Therapy for autoimmune conditions and the latest GLP-1 Medications for metabolic management. Modern Diabetes Management Technology (CGMs and Insulin Pumps) is increasingly tested. Understanding the cost-benefit and Healthcare Resource Allocation for these advanced treatments is essential for the 2026 objectives.